EVALUATION OF ENEMAS CONTAINING SUCRALFATE IN TISSUE CONTENT OF MUC-2 PROTEIN IN EXPERIMENTAL MODEL OF DIVERSION COLITIS

Oscar Orlando Araya Fernandez, José Aires Pereira, Fábio Guilherme Campos, Carolina Mardegan Araya, Gabriele Escocia Marinho, Rafaela de Souza Novo, Thais Silva de Oliveira, Yara Tinoco Franceschi, Carlos Augusto Real Martinez, Oscar Orlando Araya Fernandez, José Aires Pereira, Fábio Guilherme Campos, Carolina Mardegan Araya, Gabriele Escocia Marinho, Rafaela de Souza Novo, Thais Silva de Oliveira, Yara Tinoco Franceschi, Carlos Augusto Real Martinez

Abstract

Background: The effects of topical application of sucralfate (SCF) on the tissue content of MUC-2 protein have not yet been evaluated in experimental models of diversion colitis.

Aim: To measure the tissue content of MUC-2 protein in the colonic mucosa diverted from fecal stream submitted to the SCF intervention.

Methods: Thirty-six rats underwent derivation of intestinal transit through proximal colostomy and distal mucous fistula. The animals were divided into three groups which were submitted application of enemas with saline, SCF 1 g/kg/day and SCF 2 g/kg/day. Each group was divided into two subgroups, according to euthanasia was done after two or four weeks. The colitis diagnosis was established by histopathological study and the inflammatory intensity was evaluated by previously validated scale. The MUC-2 protein was identified by immunohistochemistry and the tissue content was measured computerized morphometry).

Results: The application of enemas with SCF in the concentration of 2 g/kg/day reduced inflammatory score of the segments that were diverted from fecal stream. The content of MUC-2 in diverted colon of the animals submitted to the intervention with SCF, independently of intervention period and the used concentration, was significantly greater than animals submitted to the application of enemas containing saline (p< 0.01). The content of MUC-2 after the intervention with SCF in the concentration of 2 g/kg/day was significantly higher when compared to the animals submitted to the application containing SCF at concentration of 1.0 g/kg/day (p<0.01). The tissue content of MUC-2 reached the highest values after intervention with SCF in the concentration of 2 g/kg/day for four weeks (p<0.01). Conclusion: The preventive application of enemas containing SCF reduces the inflammatory score and avoids the reduction of tissue content of MUC-2, suggesting that the substance is a valid therapeutic strategy to preserve the mucus layer that covers the intestinal epithelium.

Conflict of interest statement

Conflicts of interest: none

Figures

FIGURE 1. Algorithm of the division of…
FIGURE 1. Algorithm of the division of experimental groups
FIGURE 2. A) Histological section of the…
FIGURE 2. A) Histological section of the colonic mucosa derived after irrigation with SF for four weeks (H&E-100x); B) histological section of the colonic mucosa derived after irrigation with SCF at the concentration of 2 g/kg/day for four weeks. A thin film of SCF covering the surface of the mucosa (H&E-200 x) is observed.
FIGURE 3. A) Histological section of a…
FIGURE 3. A) Histological section of a colonic segment where there is a reduction of MUC-2 expression after irrigation with SF for four weeks (100x); B) colonic segment, where higher MUC-2 expression was observed after irrigation with SCF at the concentration of 1 g/kg/day for four weeks when compared to irrigation with SF (100x); C) derived colic segment where MUC-2 expression was increased on the epithelial surface after irrigation with SCF at a concentration of 2 g/kg/day for four weeks when compared to animals irrigated with SF and SCF 1 g/kg/day (100x).
FIGURE 4. Tissue content of MUC-2 in…
FIGURE 4. Tissue content of MUC-2 in control, SCF-1 and SCF-2 animals submitted to daily intervention with SCF for two and four weeks

References

    1. Augenlicht L, Shi L, Mariadason J, Laboisse C, Velcich A. Repression of MUC-2 gene expression by butyrate, a physiological regulator of intestinal cell maturation. Oncogene. 2003;22(32):4983–4992.
    1. Awad AB, Kamei A, Horvath PJ, Fink CS. Prostaglandin synthesis in human cancer cells influence of fatty acids and butyrate. Prostaglandins Leukot Essent Fatty Acids. 1995;53(2):87–93.
    1. Bonassa CEG, Pereira JA, Campos FGCM, Rodrigues MR, Sato DT, Chaim FDM, Martinez CAR. Tissue content of sulfomucins and sialomucins in the colonic mucosa, without fecal stream, undergoing daily intervention with sucralfate. Acta Cir Bras. 2015;30(5):328–338.
    1. Burger-van Paassen N, Vincent A, Puiman PJ, van der Sluis M, Bouma J, Boehm G, van Goudoever JB, van Seuningen I, Renes IB. The regulation of intestinal mucin MUC2 expression by short-chain fatty acids: implications for epithelial protection. Biochem J. 2009;420(2):211–219. doi: 10.1042/BJ20082222..
    1. Chaim FDM, Sato DT, Rodrigues MR, Dias AM, Silveira PP, Júnior, Pereira JA, Martinez CAR. Evaluation of the application of enemas containing sucralfate in tissue content of neutral and acid mucins in experimental model of diversion colitis. Acta Cir Bras. 2014;29(9):544–552.
    1. Daly K, Shirazi-Beechey SP. Microarray analysis of butyrate regulated gene in colonic epithelial cells. DNA Cell Biol. 2006;25(1):49–62. doi: 10.1089/dna.2006.25.49.
    1. Deplancke B, Gaskins HR. Microbial modulation of innate defense goblet-cells and the intestinal mucus layer. Am J Clin Nutr. 2001;73(6):1131S–1141S.
    1. Finnie IA, Dwarakanath AS, Taylor BA, Rhodes JM. Colonic mucins synthesis is increased by sodium butyrate. Gut. 1995;36(1):93–99.
    1. Gaudier E, Hoebler C. Physiological role of mucins in the colonic barrier integrity. Gastroenterol Clin Biol. 2006;30(8-9):965–974.
    1. Gaudier E, Jarry A, Blottière HM, De Coppet P, Buisine MP, Aubert JP, Laboisse C, Cherbut C, Hoebler C. Butyrate specifically modulates MUC gene expression in intestinal epithelial goblet cells deprived of glucose Am. J. Physiol. Gastrointest Liver Physiol. 2004;287(6):G1168–G1174.
    1. Gaudier E, Rival M, Buisine MP, Robineau I, Hoebler C. Butyrate enemas upregulate MUC genes expression but decrease adherent mucus thickness in mice colon. Physiol Res. 2009;58(1):111–119.
    1. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota introducing the concept of prebiotics. J. Nutr. 1995;125(6):1401–1412.
    1. Glotzer DJ, Glick ME, Goldman H. Proctitis and colitis following diversion of fecal stream. Gastroenterology. 1981;80(3):438–441.
    1. Hamer HM, Jonkers DM, Vanhoutvin SA, Troost FJ, Rijkers G, de Bruïne A, Bast A, Venema K, Brummer RJ. Effect of butyrate enemas on inflammation and antioxidant status in the colonic mucosa of patients with ulcerative colitis in remission. Clin Nutr. 2010;29(6):738–744.
    1. Hatayama H, Iwashita J, Kuwajima A, Abe T. The short chain fatty acid, butyrate, stimulates MUC2 mucin production in the human colon cancer cell line, LS174T. Biochem Biophys Res Commun. 2007;356(3):599–603.
    1. Hollander D, Tarnawski A, Gergely H, Zipser RD. Sucralfate protection of the gastric mucosa against ethanol-induced injury a prostaglandin-mediated process? Scand J Gastroenterol Suppl. 1984;101:97–102.
    1. Keli E, Bouchoucha M, Devroede G, Carnot F, Ohrant T, Cugnenc PH. Diversion related experimental colitis in rats. Dis Colon Rectum. 1997;40(2):222–228.
    1. Konturek SJ, Kwiecien N, Obtulowicz W, Kopp B, Oleksy J. Double blind controlled study on the effect of sucralfate on gastric prostaglandin formation and microbleeding in normal and aspirin treated man. Gut. 1986;27(12):1450–1456.
    1. Lameiro TMM, da Silva CMG, Marques LHS, Cunha FL, Almeida MG, Pereira JA, Martinez CAR. Effects of butyrate on levels of lipid peroxidation in cells of the colonic mucosa without fecal stream: experimental study in rats. Rev bras. colo-proctol. 2011;31(2):155–164. doi: 10.1590/S0101-98802011000200007.
    1. Laudanno OM, Bedini OA, Cesolari JA, San Miguel P. Evidence of anti-oxidant role of sucralfate in gastric mucosal protection. Ital J Gastroenterol. 1990;22(1):19–21.
    1. Martinez CAR, Nonose R, Spadari APP, Máximo FR, Priolli DG, Pereira JA, Margarido NF. Quantification by computerized morphometry of tissue levels of sulfomucins and sialomucins in diversion colitis in rats. Acta Cir Bras. 2010;25(3):231–240.
    1. Martinez CAR, Ribeiro ML, Gambero A, Miranda DDC, Pereira JA, Nadal SR. The importance of oxygen free radicals in the etiopathogenesis of diversion colitis in rats. Acta Cir Bras. 2010;25(5):387–395.
    1. Martinez CAR, Rodrigues MR, Sato DT, da Silva CMG, Kanno DT, Mendonça RLS, Pereira JA. Evaluation of the anti-inflammatory and antioxidant effects of the sucralfate in diversion colitis. J. Coloproctol. (Rio J.) 2015;35(2):90–99. doi: 10.1016/j.jcol.2015.02.007..
    1. Mello RO, Silva CM, Fonte FP, Silva DL, Pereira JA, Margarido NF, Martinez CA. Evaluation of the number of goblet cells in crypts of the colonic mucosa with and without fecal transit. Rev Col Bras Cir. 2012;39(2):139–145.
    1. Nassri CGG, Nassri AB, Favero E, Rotta CM, Martinez CAR, Margarido NF. Influence of irrigation of nutritional solutions in the colon excluded of fecal stream. Experimental study in rats. Rev bras colo-proctol. 2008;28(3):306–314. doi: 10.1590/S0101-98802008000300006..
    1. Nonose R, Spadari APP, Priolli DG, Máximo FR, Pereira JA, Martinez CAR. Tissue quantification of neutral and acid mucins in the mucosa of the colon with and without fecal stream in rats. Acta Cir Bras. 2009;24(4):267–275. doi: 10.1590/S0102-86502009000400005..
    1. Pereira JA, Rodrigues MR, Sato DT, Silveira PP, Júnior, Dias AM, Silva CG, Martinez CAR. Evaluation of sucralfate enema in experimental diversion colitis. J. Coloproctol (Rio J.) 2013;33(4):182–190. doi: 10.1016/j.jcol.2013.08.005.
    1. Pravda J. Radical induction theory of ulcerative colitis World J. Gastroenterology. 2005;11(16):2371–2384.
    1. Sauer J, Richter KK, Pool-Zobel BL. Physiological concentrations of butyrate favorably modulate genes of oxidative and metabolic stress in primary human colon cells. J Nutr Biochem. 2007;18(11):736–745.
    1. Scheiman JM, Kraus ER, Yoshimura K, Boland CR. Effect of sucralfate on components of mucosal barrier produced by cultured canine epithelial cells in vitro. Dig Dis Sci. 1992;37(12):1853–1859.
    1. Slomiany BL, Piotrowski J, Tamura S, Slomiany A. Enhancement of the protective qualities of gastric mucus by sucralfate role of phosphoinositides. Am J Med. 1991;91(2A):30S–36S.
    1. Sobrado CW, Sobrado LF. Management of acute severe ulcerative colitis: a clinical update. Arq Bras Cir Dig. 2016;29(3):201–205. doi: 10.1590/0102-6720201600030017..
    1. Swidsinski A, Loening-Baucke V, Theissig F, Engelhardt H, Bengmark S, Koch S, Lochs H, Dörfel Y. Comparative study of the intestinal mucus barrier in normal and inflamed colon. Gut. 2007;56(3):343–350.
    1. Tong LC, Wang Y, Wang ZB, Liu WY, Sun S, Li L, Su DF, Zhang LC. Propionate ameliorates dextran sodium sulfate-induced colitis by improving intestinal barrier function and reducing inflammation and oxidative stress. Front Pharmacol. 2016;7:253–253.
    1. Wachtershauser A, Stein J. Rationale for the luminal provision of butyrate in intestinal diseases. Eur J Nutr. 2000;39(4):164–171.
    1. Willemsen LE, Koetsier MA, Van Deventer SJ, Van Tol EA. Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin E1 and E2 production by intestinal myofibroblasts. Gut. 2003;52(10):1442–1447.
    1. Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic health fermentation and short chain fatty acids. J Clin Gastroenterol. 2006;40(3):235–243.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera